Received May 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 7PK53 | — |
pediatric dose of Havrix to a 62 years old female patient; pediatric dose of Havrix to a 62 years old female patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 62-year-old female patient who received HAV (Havrix pediatric) (batch number 7PK53, expiry date 20-MAR-2026) for prophylaxis. Previously administered products included Havrix adult (received 1st dose of Havrix on unknown date). On 04-JAN-2025, the patient received the 2nd dose of Havrix pediatric. On 04-JAN-2025, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: pediatric dose of Havrix to a 62 years old female patient) and underdose (Verbatim: pediatric dose of Havrix to a 62 years old female patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 08-MAY-2025 The pharmacist called to report that they administered a pediatric dose of Havrix to a 62 years old female patient, which led to adult use of a child product and underdose. This pediatric dose of Havrix was administered on 4/JAN/2025 and was her second dose of the series.